Insmed (INSM) Misses Q1 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Insmed (INSM) Misses Q1 EPS by 5c

Insmed Reports First Quarter 2015 Financial Results

May 7, 2015 8:04 AM EDT

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on developing orphan treatments for rare pulmonary diseases, today reported financial results for the quarter ended March 31, 2015.

First quarter and recent highlights include:

Validation of the companys Marketing Authorization Application (MAA) for ARIKAYCE by the European Medicines Agency (EMA). Advancement of the companys phase 3 global 212 study of patients with treatment-resistant nontuberculous mycobacteria (NTM), lung infections with the opening of multiple clinical trial sites. Acceptance... More